Merck announces Week 96 data from Phase 2b study evaluating Islatravir in combination with Doravirine in adults with HIV-1 infection
Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified Company Also Presenting Phase 1/1b Results for MK-8507, a New Investigational Once-Weekly Oral HIV Agent; Company Advances MK-8507 to Phase 2 KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known